FLXN: Flexion Therapeutics, Inc. - Summary | Jitta

Flexion Therapeutics, Inc.

NASDAQ:FLXN

Notice
Stock data is unavailable or the company’s delisted.
Price
$9.12
Loss Chance
54.3%
2.52JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (46)
Recent Business Performance (63)
Financial Strength (30)
Return to Shareholders (13)
Competitive Advantage (47)
Jitta Signs
Recent Business PerformanceEarning decline 26.60% in the last quarter (yoy)
New Share IssuedMore than 50% in 5 years
CapExVery High
Key Stats
Jitta Score
Jitta Line
2.52
100.00%
2.03
311.01%
2.03
311.01%
COMPANY DESCRIPTION
Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions in the United States. The company offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) knee pain. It is also involved in the development of FX201, a gene therapy product candidate designed to provide on demand production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee; and FX301, a NaV1.7 inhibitor for the management of post-operative pain. The company was founded in 2007 and is headquartered in Burlington, Massachusetts. As of November 19, 2021, Flexion Therapeutics, Inc. operates as a subsidiary of Pacira BioSciences, Inc..